Metabolic syndrome (MetS) is characterized by the presence of at least three interrelated risk factors, including
central obesity,
hypertension, elevated serum
triglycerides, low serum
high-density lipoproteins, and
insulin resistance.
Abdominal obesity is considered a predominant risk factor. Lifestyle changes with medications to lower
cholesterol,
blood sugar, and
hypertension are the general treatment approaches. Functional foods and bioactive
food ingredients represent versatile tools for addressing different aspects of MetS. In a randomized placebo-controlled clinical study, we evaluated the effect of
Calebin A, a minor bioactive
phytochemical from Curcuma longa, on
metabolic syndrome in obese adults (N = 100), and 94 individuals completed the study (N = 47 in both groups). They were subjected to
Calebin A supplementation for 90 days, which resulted in a statistically significant reduction in their
body weight, waist circumference, body mass index,
low-density lipoprotein-cholesterol, and
triglyceride levels compared to those with the placebo. A small but significant increase in
high-density lipoprotein-cholesterol levels was also observed in these individuals. Furthermore,
Calebin A showed a positive effect on
adipokines by reducing circulating
leptin levels. Finally,
C-reactive protein levels were significantly reduced in
Calebin A-supplemented individuals, suggesting a beneficial impact on managing MetS-induced
inflammation.
Blood glucose levels,
insulin resistance, and blood pressure levels were not affected by
Calebin A. In conclusion,
Calebin A may be an effective supplement for managing
abdominal obesity,
dyslipidemia, and systemic
inflammation in individuals with
metabolic syndrome. This study was prospectively registered on the Clinical Trial Registry of India (CTRI) with the registration number CTRI/2021/09/036495. https://ctri.nic.in/Clinicaltrials/advancesearchmain.php.